Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic alterations in bladder cancer

G Dalbagni1, J Presti, V Reuter

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Lancet (London, England)
|August 21, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays.

British journal of cancer·2024
Same author

Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients.

Actas urologicas espanolas·2021
Same author

Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. Reply.

The Journal of urology·2021
Same author

The impact of fluid optimisation before induction of anaesthesia on hypotension after induction.

Anaesthesia·2020
Same author

Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Virchows Archiv : an international journal of pathology·2020
Same author

Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2019
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Genetic alterations in bladder cancer progression were studied. Early stage bladder tumors show 9q deletions, while invasive cancers exhibit 3p, 5q, and 17p deletions, indicating distinct genetic pathways in tumor development.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Bladder cancer progression involves genetic alterations.
  • Understanding the sequence of these genetic events is crucial for predicting clinical outcomes.

Purpose of the Study:

  • To investigate the sequential genetic alterations in bladder cancer development.
  • To correlate specific chromosomal abnormalities with tumor stage and clinical outcome.

Main Methods:

  • Analysis of 60 paired bladder tumors and normal tissues using polymorphic DNA markers.
  • Assessment of loss of heterozygosity (LOH) at candidate tumor suppressor gene sites.
  • Correlation of genotypic patterns with pathological indices of tumor progression.

Main Results:

Related Experiment Videos

  • Distinct genotypic patterns were associated with early (Ta) and late stages of bladder cancer.
  • 9q deletions were prevalent in superficial papillary tumors (Ta) and those invading the lamina propria (T1).
  • 3p, 5q, and 17p deletions were absent in Ta tumors but present in invasive bladder cancers, with 9qLOH decreasing in muscle-invasive stages.

Conclusions:

  • Two distinct genetic pathways characterize the evolution of superficial bladder tumors.
  • Specific chromosomal abnormalities play defined roles in bladder tumor development.
  • Other genetic alterations correlate with pathological indices of poor clinical outcome in bladder cancer.